X-Ray Crystallography Reveals the Two Faces of Flavivirus Nonstructural Protein
|
By LabMedica International staff writers Posted on 17 Feb 2014 |

Image: The external face of the Flavivirus NS1 protein (sugars in grey balls) is exposed on infected cell surfaces where it can interact with the immune system. This face is also exposed in secreted NS1 particles present in patient sera. The background image shows artificial membranes coated with the NS1 protein (Photo courtesy of the University of Michigan).
High-resolution X-ray crystallography and electron microscopy have revealed that the Flavivirus NS1 (nonstructural protein 1) has two distinct faces, one that interacts with the interior of the infected host cell and the other that is exposed to antiviral elements in the host's immune system.
Flaviviruses are responsible for several severe diseases of humans including dengue fever, West Nile fever, tick-borne encephalitis, and yellow fever. All the flaviviruses produce nonstructural protein 1 (NS1), which functions in genome replication as an intracellular dimer and in immune system evasion as a secreted hexamer. In general, nonstructural proteins are encoded by the viral genome and are produced in the organisms they infect, but are not packaged into the virus particles. Some of these proteins may play roles within the infected cell during virus replication or act in regulation of virus replication or virus assembly.
Investigators at the University of Michigan (Ann Arbor, USA) and colleagues at Purdue University (Lafayette, IN, USA) chose X-ray crystallography as an approach to developing a better understanding of how NS1 functions.
The investigators isolated and crystallized NS1 from Dengue virus and West Nile virus. They then created a three-dimensional atomic structure map of the protein crystals based on data obtained from X-ray crystallography carried out at the Advanced Photon Source at the Argonne National Laboratory (Illinois, USA). Subsequently, electron microscopy was used to elucidate how NS1 associated with membranes of infected cells.
The investigators reported the crystal structures for full-length, glycosylated NS1 from West Nile and dengue viruses in the February 6, 2014, online edition of the journal Science. Their results revealed that the NS1 hexamer in crystal structures was similar to a solution hexamer visualized by single-particle electron microscopy. Recombinant NS1 bound to lipid bilayers and remodeled large liposomes into lipoprotein nanoparticles. The NS1 structures revealed distinct domains for membrane association of the dimer and interactions with the immune system, and will form a basis for elucidating the molecular mechanism of NS1 function.
"Isolating the protein in order to study it has been a challenge for researchers," said senior author Dr. Janet Smith, professor of biological chemistry at the University of Michigan. "Once we discovered how to do that, it crystallized beautifully. Seeing the design of this key protein provides a target for a potential vaccine or even a therapeutic drug."
"The two faces of NS1 define the regions responsible for its two major functions," said Dr. Smith. "This understanding will guide future research into dissecting and targeting these regions in disease treatment or prevention. We are now collaborating with the Purdue virologists to understand exactly how the two faces of NS1 help the virus survive and thrive in patients. These studies are the next steps toward a vaccine or an antiviral drug."
Related Links:
University of Michigan
Purdue University
Argonne National Laboratory
Flaviviruses are responsible for several severe diseases of humans including dengue fever, West Nile fever, tick-borne encephalitis, and yellow fever. All the flaviviruses produce nonstructural protein 1 (NS1), which functions in genome replication as an intracellular dimer and in immune system evasion as a secreted hexamer. In general, nonstructural proteins are encoded by the viral genome and are produced in the organisms they infect, but are not packaged into the virus particles. Some of these proteins may play roles within the infected cell during virus replication or act in regulation of virus replication or virus assembly.
Investigators at the University of Michigan (Ann Arbor, USA) and colleagues at Purdue University (Lafayette, IN, USA) chose X-ray crystallography as an approach to developing a better understanding of how NS1 functions.
The investigators isolated and crystallized NS1 from Dengue virus and West Nile virus. They then created a three-dimensional atomic structure map of the protein crystals based on data obtained from X-ray crystallography carried out at the Advanced Photon Source at the Argonne National Laboratory (Illinois, USA). Subsequently, electron microscopy was used to elucidate how NS1 associated with membranes of infected cells.
The investigators reported the crystal structures for full-length, glycosylated NS1 from West Nile and dengue viruses in the February 6, 2014, online edition of the journal Science. Their results revealed that the NS1 hexamer in crystal structures was similar to a solution hexamer visualized by single-particle electron microscopy. Recombinant NS1 bound to lipid bilayers and remodeled large liposomes into lipoprotein nanoparticles. The NS1 structures revealed distinct domains for membrane association of the dimer and interactions with the immune system, and will form a basis for elucidating the molecular mechanism of NS1 function.
"Isolating the protein in order to study it has been a challenge for researchers," said senior author Dr. Janet Smith, professor of biological chemistry at the University of Michigan. "Once we discovered how to do that, it crystallized beautifully. Seeing the design of this key protein provides a target for a potential vaccine or even a therapeutic drug."
"The two faces of NS1 define the regions responsible for its two major functions," said Dr. Smith. "This understanding will guide future research into dissecting and targeting these regions in disease treatment or prevention. We are now collaborating with the Purdue virologists to understand exactly how the two faces of NS1 help the virus survive and thrive in patients. These studies are the next steps toward a vaccine or an antiviral drug."
Related Links:
University of Michigan
Purdue University
Argonne National Laboratory
Latest BioResearch News
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








